Biopharmx Corp (NASDAQ:BPMX)’s share price traded up 3.3% during trading on Thursday . The company traded as high as $0.31 and last traded at $0.29. 376,857 shares were traded during mid-day trading, a decline of 45% from the average session volume of 681,161 shares. The stock had previously closed at $0.30.
A number of equities analysts have recently commented on the company. Maxim Group reiterated a “buy” rating and issued a $3.00 price objective on shares of Biopharmx Corp in a research note on Friday, June 2nd. Roth Capital set a $3.00 price objective on Biopharmx Corp and gave the stock a “buy” rating in a research note on Saturday, June 3rd. Finally, HC Wainwright set a $3.00 price objective on Biopharmx Corp and gave the stock a “buy” rating in a research note on Thursday, June 15th.
Biopharmx Corp (NASDAQ:BPMX) last issued its earnings results on Wednesday, September 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06). Biopharmx Corp had a negative net margin of 28,405.26% and a negative return on equity of 1,847.04%. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million.
In other news, major shareholder Franklin Resources Inc bought 250,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was acquired at an average cost of $0.34 per share, for a total transaction of $85,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
A number of hedge funds have recently modified their holdings of BPMX. Virtu KCG Holdings LLC lifted its position in Biopharmx Corp by 366.2% during the second quarter. Virtu KCG Holdings LLC now owns 503,418 shares of the company’s stock worth $241,000 after acquiring an additional 395,424 shares during the last quarter. Vanguard Group Inc. lifted its position in Biopharmx Corp by 324.6% during the second quarter. Vanguard Group Inc. now owns 1,933,747 shares of the company’s stock worth $927,000 after acquiring an additional 1,478,338 shares during the last quarter. Finally, Vivo Capital LLC lifted its position in Biopharmx Corp by 10.0% during the second quarter. Vivo Capital LLC now owns 14,096,338 shares of the company’s stock worth $6,752,000 after acquiring an additional 1,282,052 shares during the last quarter.
Biopharmx Corp Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.